MGNX:NASDAQMacroGenics, Inc. Analysis
Data as of 2026-05-24 - not real-time
$4.53
Latest Price
8/10Risk
Risk Level: High
Executive Summary
MacroGenics (MGNX) trades at $4.53, well above its 20‑day SMA of $3.55 and its 50‑day SMA of $3.33, indicating bullish price momentum supported by a bullish MACD histogram (+0.12) and RSI of 71.3.
Technical signals are reinforced by extreme‑greed sentiment (Fear/Greed Index 91.6) and a sharply rising volume trend, yet the stock exhibits very high 30‑day volatility (≈89 %) and a historic max drawdown of –34 %.
Fundamentally, the company posts negative gross (‑19 %) and operating margins (‑161 %), a trailing EPS of –$1.11 and a debt‑to‑equity of 172×, underscoring deep value concerns despite a recent $122.5 M cash infusion from the Bora sale and a $60 M payment from Sagard that improve liquidity.
The DCF‑derived fair price of $8.48 suggests the market is undervaluing the stock, while the upside/downside metric of +49 % points to modest upside potential if the pipeline can be monetized.
Technical signals are reinforced by extreme‑greed sentiment (Fear/Greed Index 91.6) and a sharply rising volume trend, yet the stock exhibits very high 30‑day volatility (≈89 %) and a historic max drawdown of –34 %.
Fundamentally, the company posts negative gross (‑19 %) and operating margins (‑161 %), a trailing EPS of –$1.11 and a debt‑to‑equity of 172×, underscoring deep value concerns despite a recent $122.5 M cash infusion from the Bora sale and a $60 M payment from Sagard that improve liquidity.
The DCF‑derived fair price of $8.48 suggests the market is undervaluing the stock, while the upside/downside metric of +49 % points to modest upside potential if the pipeline can be monetized.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- recent cash infusion from Bora and Sagard
- high upside/downside metric (+49%)
- bullish technical indicators (MACD, RSI, SMA crossover)
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- cash infusion improves balance sheet and reduces leverage
- DCF fair value ($8.48) indicates price upside
- potential pipeline monetization pending clinical milestones
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- persistent negative margins and operating losses
- high biotech regulatory and clinical risk
- elevated debt‑to‑equity ratio (172×) despite cash receipts
Key Metrics & Analysis
Financial Health
Revenue Growth57.50%
Profit Margin-44.79%
P/E Ratio-3.2
ROE-140.27%
ROA-17.98%
Debt/Equity172.23
P/B Ratio5.2
Op. Cash Flow$-69961000
Free Cash Flow$11.8M
Industry P/E27.6
Technical Analysis
TrendBullish
RSI71.3
Support$2.85
Resistance$4.64
MA 20$3.55
MA 50$3.33
MA 200$2.11
MACDBullish
VolumeIncreasing
Fear & Greed Index91.61
Valuation
Fair Value$8.48
Target Price$6.75
Upside/Downside49.01%
GradeUndervalued
TypeValue
Risk Assessment
Beta1.55
Volatility89.37%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.